EICHORCondition: Epilepsy · Healthy Volunteer · Sponsor: Suninflam Inc
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy
This description comes directly from the study's public registry record.
Dongxu Sun, PhD · 6507850225 · dsun@suninflam.com
Always discuss trial participation with your own doctor first.
| Center for Neurosciences | Tucson, Arizona, United States | Recruiting |
| Accel Research sites network | DeLand, Florida, United States | Recruiting |
| D&H Tamarac Research Center, LLC | Tamarac, Florida, United States | Recruiting |
| Encore Medical Research of Weston, LLC | Weston, Florida, United States | Recruiting |
| Hawaii Pacific Neuroscience, Comprehensive Epilepsy Center | Honolulu, Hawaii, United States | Recruiting |
| Mid-Atlantic Epilepsy and Sleep Center | Bathesda, Maryland, United States | Recruiting |
| Quest Research Institute | Farmington Hills, Michigan, United States | Recruiting |
| Dent Neurologic Institute | Amherst, New York, United States | Recruiting |
| OnSite Clinical Solutions, LLC | Charlotte, North Carolina, United States | Recruiting |
| Horizon Clinical Research Center | Cypress, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07051629